AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06224036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethylpyrazine rifampicide (II)
Description: Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
Study NCT04629443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 64315 (also referred as MIK665) and azacitidine
Description: The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days.
Study NCT05817214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
Study NCT05817214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
Study NCT05817214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
Study NCT06511115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Each session will be divided into three clearly differentiated parts:~i) A 5-minute warm-up consisting of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise. This portion will include flexibility and stretching movements, as well as joint mobility exercises; ii) 35 minutes dedicated to the main section of the intervention using the Nintendo Wii to promote physical, mental, and cognitive activity; iii) 5 minutes for relaxation techniques that incorporate flexibility exercises and stretches.~Each session will be led by a qualified and experienced professional. No incidents of injuries or negative effects were reported during the intervention period. Throughout the 12-week intervention, participants will be periodically followed up by phone to inquire about their physical activity habits.
Study NCT04295213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oligosaccharides
Description: 1 dose a day of oligosaccharides or placebo
Study NCT04295213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oligosaccharides
Description: 1 dose a day of oligosaccharides or placebo
Study NCT05062720 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local consolidative therapy
Description: Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
Study NCT05148702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic - standard duration
Description: Clinician decided antibiotic and duration of treatment
Study NCT05148702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic - fixed-extended-duration
Description: Clinician decided antibiotic for a fixed duration of 28 days.
Study NCT05897983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado exercises plus TENS device
Description: Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
Study NCT05663164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B
Description: vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
Study NCT05663164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study NCT05865171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablets for oral administration.
Study NCT05105568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process-based therapy
Description: Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
Study NCT04472845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1 week RT
Description: RT will be delivered over 1 week
Study NCT04472845 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 2 week RT
Description: RT will be delivered over 2 week
Study NCT06001866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-based verb learning
Description: Learning sessions: Novel verbs are practiced on Day 1. In one condition, the words are learned using repeated spaced retrieval practice - retrieval trials are initially immediate, then occur after 3 intervening words. In the other condition, the words and video are presented without retrieval trials. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word in the context of a sentence twice with actors and objects viewed during learning and twice with new actors and objects. One week after Day 1, this recall test is completed again. At this time, the child's ability to generalize the verb to a new sentence frame will be assessed. Finally, the child will complete a recognition test: viewing pairs of video clips, the child will hear each novel verb and point to the video clip that depicts that action.
Study NCT04331132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolvaptan 15 MG
Description: vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
Study NCT04331132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan 15 MG
Description: vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
Study NCT05062720 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Local consolidative therapy
Description: Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
Study NCT06155032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular therapy
Description: Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.
Study NCT06155032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.
Study NCT06155032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
Study NCT04674254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
Study NCT04674254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted retinal photocoagulation
Description: Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.
Study NCT04674254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard pan-retinal photocoagulation
Description: Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
Study NCT06168747 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Joint Mobilization
Description: Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
Study NCT06168747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Joint Mobilization
Description: Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
Study NCT05456854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperglycemic Clamp
Description: Administration of a hyperglycemic clamp
Study NCT05456854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycemic Clamp
Description: Administration of a hyperglycemic clamp
Study NCT05456854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10
Description: Administration of kisspeptin-10 \* 16 hr
Study NCT05456854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo \*16 hr
Study NCT05827588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWAK PD
Description: Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
Study NCT05464121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.
Description: The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention.
Study NCT06572943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Description: Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
Study NCT06154174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-RUTF (Ready-to-Use Therapeutic Food with added choline)
Description: Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
Study NCT06154174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-RUTF (Ready-to-Use Therapeutic Food without added choline)
Description: Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
Study NCT06154174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral amoxicillin tablets twice per day for 7 days dosed based on weight
Study NCT06154174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral amoxicillin tablets twice per day for 7 days dosed based on weight
Study NCT04978077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)
Description: After a night fast participants will drink the test meal
Study NCT06150469 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Blend of ginger and lemon essential oils, Neutral oil
Description: Patients will be given aromasticks to inhale the blend of essential oils.
Study NCT06150469 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Blend of ginger and lemon essential oils, Neutral oil
Description: Patients will be given aromasticks to inhale the blend of essential oils.
Study NCT06640881 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ablative single-dose PBI
Description: ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
Study NCT06364176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Treatment with losartan through week 12
Study NCT06364176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo through week 12
Study NCT05708300 — intervention group
Intervention type: DRUG
Intervention: Mepolizumab 100 MG [Nucala]
Description: subcutaneous injection once a month
Study NCT04761692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full VEPMP Intervention
Description: Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
Study NCT04761692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial VEPMP Intervention
Description: Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
Study NCT04761692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed VEPMP Intervention
Description: Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
Study NCT04678765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided distal peripheral nerve block
Description: To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease.
Study NCT04678765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadruple-injection axillary nerve block
Description: The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited.
Study NCT06009744 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Low-dose vitamin C and zinc
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
Study NCT06009744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose vitamin C and zinc
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
Study NCT05559684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.
Study NCT05559684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus thoracis plane block
Description: Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
Study NCT04765670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
Study NCT04765670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape Application
Description: Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
Study NCT05271123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of respiratory function and growth motor function classiffication level
Description: Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs